

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449/PTO

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT BY
APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2 Attorney Docket No. 7541-5

Complete if Known

Application Number	10/561,529
Filing Date	December 20, 2005
First Named Inventor	SAMARITANI, Fabrizio et al.
Art Unit	1647
Examiner Name	Lorraine Spector

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.*	Document Number Number-Kind Code ² (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US 4,496,537	01-29-1985	Kwan, Henry K.	
		US 4,589,402	05-20-1986	Hodgen, et al.	
		US 4,659,696	04-21-1987	Hirai, et al.	
		US 4,670,419	06-02-1987	Uda, et al.	
		US 4,746,508	05-24-1998	Carey, et al.	
		US 4,496,537	01-29-1985	Kwan, Henry K.	
		US 4,962,091	10-09-1990	Eppstein, et al.	
		US 5,087,615	02-11-1992	Chappel, et al.	
		US 5,128,453	07-07-1992	Arpaia, et al.	
		US 5,162,306	11-10-1992	Donaldson	
		US 5,270,057	12-14-1993	de Meere, et al.	
		US 5,356,876	10-18-1994	Espey, Lawrence L.	
		US 5,374,620	12-20-1994	Clark, et al.	
		US 5,384,132	01-24-1995	De Meere, et al.	
		US 5,508,261	04-16-1996	Moyle, et al.	
		US 5,580,856	12-03-1996	Prestreiski, et al.	
		US 5,639,640	06-17-1997	Reddy, et al.	
		US 5,650,390	07-22-1997	Samaritani, et al.	
		US 5,661,125	08-26-1997	Strickland, Thomas Wayne	
		US 5,681,822	10-28-1997	Bornstein, et al.	
		US 5,733,572	03-31-1998	Unger, et al.	
		US 5,767,067	06-16-1998	Arpaia, et al.	
		US 5,811,096	09-22-1998	Aleman, et al.	
		US 5,889,110	03-30-1999	Hutchinson, et al.	
		US 5,929,028	07-27-1999	Skrabanja, et al.	
		US 5,945,187	08-31-1999	Buch-Rasmussen, et al.	
		US 6,066,620	05-23-2000	McGregor, et al.	
		US 6,136,784	10-24-2000	L'Italien, et al.	
		US 6,238,890	05-29-2001	Boime, et al.	
		US 6,267,958	07-31-2004	Andya, et al.	
		US 6,440,930	08-27-2002	Rinella, Jr., Vincent Joseph	

Examiner Signature	/Elly Gerald Stoica/	Date Considered	06/09/2008
--------------------	----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 31).⁴ If Japanese patent documents, the indicate of the year of the reign of the emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.G.S./

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT BY
APPLICANT**

(Use as many sheets as necessary)

Sheet	2	of	2	Attorney Docket No.	7541-5
-------	---	----	---	---------------------	--------

MAY 17 2007
U.S. PATENT AND TRADEMARK OFFICE
BY COUNSEL FOR APPLICANT



U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (If known)			
	US	6,541,606	04-01-2003	Margolin, et al.	
	US	6,573,237	06-03-2003	Rinella, Jr., Vincent Joseph	
	US	2003/0072803	04-27-2003	Goldenberg, et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (If known)			T ⁶
	DE	41 17 078 A1	11-25-1882	Lohmann, et al.	<input type="checkbox"/>
	EP	0 318 081	05-31-1989	Jansen, et al.	<input type="checkbox"/>
	EP	0 448 146	09-25-1991	De Ruiter, Marinus Arie	<input type="checkbox"/>
	EP	0 603 159	06-22-1994	Pearlman, et al.	<input type="checkbox"/>
	EP	0 652 766	07-29-1993	O'Connor, et al.	<input type="checkbox"/>
	EP	0 668 073	04-14-1999	Igari, et al.	<input type="checkbox"/>
	EP	0 736 303	08-25-1999	Gross, et al.	<input type="checkbox"/>
	EP	0 853 945	07-22-1998	Skrabanja, et al.	<input type="checkbox"/>
	EP	0 891 774	01-20-1999	Takada, et al.	<input type="checkbox"/>
	EP	0 920 873	12-07-1998	Chang, et al.	<input type="checkbox"/>
	EP	0 974 359	01-26-2000	Hoffmann, et al.	<input type="checkbox"/>
	EP	1 191 099	06-30-1999	Itoh, et al.	<input type="checkbox"/>
	CA	1,340,132	11-17-1998	Donaldson, Lloyd E.	<input type="checkbox"/>
	FR	2782455	02-25-2000	Aleman, et al.	<input type="checkbox"/>
	GB	1065127	04-12-1967	Serono 1 st Farm	<input type="checkbox"/>
	GB	839,300	08-25-1958	Organon Laboratories Limited	<input type="checkbox"/>
	WO	92/21332	12-10-1992	Lohmann, et al.	<input type="checkbox"/>
	WO	92/22568	12-23-1992	Moyle, et al.	<input type="checkbox"/>
	WO	93/11788	06-24-1993	Samaritani, et al.	<input type="checkbox"/>
	WO	94/03198	02-17-1994	O'Connor, et al.	<input type="checkbox"/>
	WO	97/04801	02-13-1997	Andya, et al.	<input type="checkbox"/>
	WO	97/17087	05-15-1997	De Young, et al.	<input type="checkbox"/>
	WO	98/30592	07-16-1998	Hein, et al.	<input type="checkbox"/>
	WO	99/21534	05-06-1999	Tallavajhala, et al.	<input type="checkbox"/>

Examiner Signature	/Elly Gerald Stoica/	Date Considered	06/09/2008
--------------------	----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

#463778

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.G.S./



Under the Patent Reform Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

WEMMH PTO/SB/08b (09-06)
Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO

Complete if Known

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT BY
APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

7

Application Number	10/561,529
Filing Date	December 20, 2005
First Named Inventor	SAMARITANI, Fabrizio et al.
Art Unit	1647
Examiner Name	Lorraine Spector

Attorney Docket No. 7541-5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published	T ²
		AKERS Michael J., "Considerations in selecting antimicrobial preservative agents for parenteral product development", Pharmaceutical Technology, May 1984, pp. 36-46.	<input type="checkbox"/>
		AKERS, Michael J., "Excipient - Drug Interactions in Parenteral Formulations", Journal of Pharmaceutical Sciences, November 2002, Vol. 91, No. 11, pp. 2283-2300	<input type="checkbox"/>
		AMIR, Syed M. et al., "Phenol, A Potent Stimulator of Adenylate Cyclase in Human Thyroid Membranes", Endocrine Research Communications, 8(2):83-95, 1981.	<input type="checkbox"/>
		A.P.L.® Injection 5 000 IU and Injection 10 000 IU, http://home.intekom.com/pharm/akromed/apl_inj.html , December 12, 2002, pp. 1-2.	<input type="checkbox"/>
		A.P.L.® (chiorionic gonadotropin for injection, USP). For Intramuscular injection Only. Physicians' Desk Reference, 51st Edition, p. 2805.	<input type="checkbox"/>
		A.P.L.®, Physicians' Desk Reference, 42nd Edition, page 625.	<input type="checkbox"/>
		A.P.L.®, Physicians' Desk Reference, 19th Edition, page 537.	<input type="checkbox"/>
		A.P.L.®, Physicians' Desk Reference, 34th Edition, page 602.	<input type="checkbox"/>
		ARZNEIFORMENLEHRE, Paul Heinz List, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 4th Edition, 1985, pp. 402-407.	<input type="checkbox"/>
		Acclimato®, Physicians' Desk Reference, 34th Edition, pp. 1005-1006.	<input type="checkbox"/>
		Acclimato®, Physicians' Desk Reference, 36th Edition, pp. 1946-1944.	<input type="checkbox"/>
		BOIME, Irving et al., "Glycoprotein Hormone Structure-Function and Analog Design", Recent Progress in Hormone Research, Vol. 54, 1999, The Endocrine Society, pp. 271-289.	<input type="checkbox"/>
		BONTEMPO, John A., "Chapter 5. Formulation Development", Development of Biopharmaceutical Parenteral Dosage Forms, pp. 109-142, published by Marcel Dekker, Inc.	<input type="checkbox"/>
		COMBARNOUS, Yves, "Molecular Basis of the Specificity of Binding of Glycoprotein Hormones to Their Receptors", Endocrine Reviews, 1992, Vol. 13, No. 4, pp. 670-691.	<input type="checkbox"/>
		CPMP Guidelines antimicrobial preservative inclusion, CPMP/CVMP/OWP/115/95, July 8, 1997, pp. 1-6.	<input type="checkbox"/>
		de MEDEIROS, S.F. et al., "Stability of Immunoreactive β -Core Fragment of hCG", Obstetrics & Gynecology, Vol. 77, No. 1, January 1991, pp. 53-59.	<input type="checkbox"/>
		Epogen®, Physicians' Desk Reference, 51st Edition, pp. 469-484.	<input type="checkbox"/>

Examiner Signature	/Elly Gerald Stoica/	Date Considered	06/09/2008
--------------------	----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional).

²Applicant is to place a check mark here if English language Translation is attached#449528

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.G.S./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/561,529
(Use as many sheets as necessary)				Filing Date	December 20, 2005
Sheet	2	of	7	First Named Inventor	SAMARITANI, Fabrizio et al.
				Art Unit	1647
				Examiner Name	Lorraine Spector
				Attorney Docket No. 7541-5	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published	T ²
		Fertinex™ (urofollitropin for injection, purified) for subcutaneous injection. <u>Physicians' Desk Reference</u> , 53 rd Edition, pp. 2988-2989, published by Medical Economics Company, Inc.	<input type="checkbox"/>
		Fertinex®, <u>Physicians' Desk Reference</u> , 53 rd Edition, pp. 3020-3022.	<input type="checkbox"/>
		Follistim™ (follitropin beta for injection). <u>Physicians' Desk Reference</u> , 53 rd Edition, pp. 2128-2132, published by Medical Economics Company, Inc.	<input type="checkbox"/>
		Follistim®, <u>Physicians' Desk Reference</u> , 54 th Edition, pp. 2022-2030.	<input type="checkbox"/>
		Follitropin®, <u>Physicians' Desk Reference</u> , 24 th Edition, pp. 1249-1250.	<input type="checkbox"/>
		FRANSSON, Jonas et al., "Solvent Effects on the Solubility and Physical Stability of Human Insulin-Like Growth Factor 1", <u>Pharmaceutical Research</u> 14(5):606-12, 1997.	<input type="checkbox"/>
		FRENKEN, L.A.M. et al., "Analysis of the Efficacy of Measures to Reduce Pain After Subcutaneous Administration of Epoetin Alfa", <u>Nephrology Dialysis Transplantation</u> 9:1295-98, 1994.	<input type="checkbox"/>
		FURUHASHI, M. et al. "Fusing the Carboxy-Terminal Peptide of the Chorionic Gonadotropin (CG) beta Subunit to the Common alpha-Subunit: Retention of O-linked Glycosylation and Enhanced in Vivo Bioactivity of Chimeric Human CG", <u>Molecular Endocrinology</u> , 1995, Vol. 9, No. 1, pages 54-63.	<input type="checkbox"/>
		GARCIA-CAMPAYO, Vincenta et al., "Design of Stable Biologically Active Recombinant Lutropin Analogs", <u>Nature Biotechnology</u> 15:663-67, 1997.	<input type="checkbox"/>
		GENNARO et al., "Parenteral Preparations", Chapter 84, <u>Remington's Pharmaceutical Sciences</u> (18th Edition, Mack Publishing. Co., 1990, see part 8 "Pharmaceutical Preparations and their Manufacture.", pp. 1545-1569.	<input type="checkbox"/>
		Glucagon, <u>Physicians' Desk Reference</u> , 19 th Edition, pp. 703-704.	<input type="checkbox"/>
		Glukort®, <u>Physicians' Desk Reference</u> , 19 th Edition, page 644.	<input type="checkbox"/>
		Gonal-F® (follitropin alfa for injection) for subcutaneous injection. <u>Physicians' Desk Reference</u> , 53 rd Edition, pp. 2991-2995, published by Medical Economics Company, Inc.	<input type="checkbox"/>
		Gonal-F® (follitropin alfa for injection) For subcutaneous injection: Package Insert Code N1900101B, manufactured by Serono Laboratories, Inc., Randolph, MA, USA, published September, 1997.	<input type="checkbox"/>
		Gonal-F®, <u>Physicians' Desk Reference</u> , 54 th Edition, pp. 2942-2946.	<input type="checkbox"/>
		HANSON, Mucciola A. et al., "Introduction to Formulation of Protein Pharmaceuticals", Chapter 7, pp. 209 - 233.	<input type="checkbox"/>

Examiner Signature	/Elly Gerald Stoica/	Date Considered	06/09/2008
--------------------	----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional).

²Applicant is to place a check mark here if English language Translation is attached.

#463330

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.G.S./
WEMMHS01 REV. 10/07

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/561,529
(Use as many sheets as necessary)				Filing Date	December 20, 2005
Sheet	3	of	7	First Named Inventor	SAMARITANI, Fabrizio et al.
				Art Unit	1647
				Examiner Name	Lorraine Spector
				Attorney Docket No.	7541-5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published	T ²
		HARVEY, Stewart C., "Antiseptics and Disinfectants; Fungicides; Ectoparasiticides", The Pharmacological Basis of Therapeutics, 6 th Edition, Chapter 41, 964-987, 1980.	<input type="checkbox"/>
		HEIKOOP, Judith C. et al., "Structure-based design and protein engineering of intersubunit disulfide bonds in gonadotropins" Nature Biotechnology, July 1997, Volume 15, pp. 658-62.	<input type="checkbox"/>
		Package insert HRF, "HRF" Injection 0,1 mg and HRF* Injection 0,5 mg", Malahyde Information Systems, 2003, pp.1-4.	<input type="checkbox"/>
		Humanotropes®, Physicians' Desk Reference, 44 th Edition, pp. 1210-1217.	<input type="checkbox"/>
		Humegon®, Physicians' Desk Reference, 54 th Edition, pp. 2095-2097.	<input type="checkbox"/>
		JORGENSEN, Jan Trost, "Improvement of Patient Convenience in Treatment with Growth Hormone", Journal of Pediatric Endocrinology, 1994, 7(2):175-180.	<input type="checkbox"/>
		KEENE et al., Expression of Biologically Active Human Folitropin in Chinese Hamster Ovary Cells. The Journal of Biological Chemistry Vol. 264(9: 4769-4775.	<input type="checkbox"/>
		KESNER, J.S. et al., "Stability of Urinary Female Reproductive Hormones Stored Under Various Conditions", Reproductive Toxicology Vol. 9, No. 3, pp. 239-244, 1995.	<input type="checkbox"/>
		LAM, Xanthe M. et al., "The Effect of Benzyl Alcohol on Recombinant Human Interferon-γ" Pharmaceutical Research, 1997, Vol. 14, No. 6, 725-729.	<input type="checkbox"/>
		LEUKINE Package Insert/Approved Text, Rev. 0230-02, Issued February, 1998, pp 1-30.	<input type="checkbox"/>
		LIVESEY J. H. et al., "Glycerol prevents loss of immunoreactive follicle-stimulating hormone and luteinizing hormone from frozen urine". Journal of Endocrinology, Vol. 98, pp. 381-384, 1983.	<input type="checkbox"/>
		LIVESEY, J. H. et al., "Effect of Time, Temperature and Freezing on the Stability of Immunoreactive LH, FSH, TSH, Growth Hormone, Prolactin and Insulin in Plasma", The Medical Unit, Princess Margaret Hospital, Christchurch 2, New Zealand, June 25, 1980, Biochem 13 (4), 1980, pp. 151-155.	<input type="checkbox"/>
		MAA, Yuh-Fun, et al., "Aggregation of recombinant human growth hormone induced by phenolic compounds", International Journal of Pharmaceutics, 1996, Vol. 140, pp. 155 – 168.	<input type="checkbox"/>
		Metrodin®, Physicians' Desk Reference, 51 st Edition, pp. 2010-2016.	<input type="checkbox"/>
		Perjeta® Physician's Desk Reference, 20 th Edition, pp. 1366-1367.	<input type="checkbox"/>

Examiner Signature	/Elly Gerald Stoica/	Date Considered	06/09/2008
--------------------	----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional).²Applicant is to place a check mark here if English language Translation is attached.

#463330

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/561,529
Sheet	4	of	7	Filing Date	December 20, 2005
				First Named Inventor	SAMARITANI, Fabrizio et al.
				Art Unit	1647
				Examiner Name	Lorraine Spector
				Attorney Docket No.	7541-5

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published			T ⁶
		Pergonat®, Physician's Desk Reference, 45 th Edition, pp. 2333-2337.			<input type="checkbox"/>
		Pergonat®, Physician's Desk Reference, 51 st Edition, pp. 2618-2620.			<input type="checkbox"/>
		Pergonat®, Physician's Desk Reference, 54 th Edition, pp. 2940-2947.			<input type="checkbox"/>
		PIMPALKHUTE, M. et al., "Radioimmunoassay of Human Follicle Stimulating Hormone/HFSH", J. Radioanal. Nucl. Chem. Letters, 1986, 103, No. 2, pp. 105-116.			<input type="checkbox"/>
		Pregnyl® Physicians' Desk Reference, 30 th Edition, page 1450.			<input type="checkbox"/>
		Pregnyl® (chorionic gonadotropin for injection, USP), Physicians' Desk Reference, 51 st Edition, p. 1878.			<input type="checkbox"/>
		Pregnyl Prescribing Information, "Pregnyl (chorionic gonadotropin for injection, USP)", Organon Inc., August 1998, pp. 1-4.			<input type="checkbox"/>
		Procrit®; Physicians' Desk Reference, 54 th Edition, page 1000.			<input type="checkbox"/>
		Profac® (chorionic gonadotropin for injection, USP) for Intramuscular Injection, Physicians' Desk Reference, 51 st Edition, pp. 2620-21.			<input type="checkbox"/>
		Profasi (chorionic gonadotropin for injection, USP) for intramuscular injection, Serono Laboratories, Inc. (revised June 1993).			<input type="checkbox"/>
		Progyn®; Physicians' Desk Reference, 19 th Edition, page 640.			<input type="checkbox"/>
		Protropins®, Physicians' Desk Reference, 44 th Edition, pp. 1002-1003.			<input type="checkbox"/>
		RAFFERTY, M.J. et al., "Safety and Tolerability of a Multidose Formulation of Epoetin Beta in Dialysis Patients", Clinical Nephrology, 54(3):240-45, 2000.			<input type="checkbox"/>
		Regular Retino®, Physicians' Desk Reference 19 th Edition, page 705.			<input type="checkbox"/>
		REMMLE Jr., Richard L. et al., "Interleukin-1 Receptor (IL-1R) Liquid Formulation Development Using Differential Scanning Calorimetry", Pharmaceutical Research, 1998, Vol. 15, No. 2 pp. 200-208.			<input type="checkbox"/>
		ROSE, M.P. et al, "Characterisation, calibration and comparison by international collaborative study of international standards for the calibration of therapeutic preparations of FSH", Journal of Endocrinology, Vol. 158, pp. 97-114, 1998.			<input type="checkbox"/>

Examiner Signature	/Elly Gerald Stoica/	Date Considered	06/09/2008
--------------------	----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional).

²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.G.S./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/561,529
(Use as many sheets as necessary)				Filing Date	December 20, 2005
Sheet	5	or	7	First Named Inventor	SAMARITANI, Fabrizio et al.
				Art Unit	1647
				Examiner Name	Lorraine Spector
				Attorney Docket No. 7541-5	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published	T ⁶
	RYAN, Robert J. et al., "Some physical and Hydrodynamic Properties of Human FSH and LH", Mayo Clinic and Mayo Foundation, Section of Endocrine Research, Rochester, Minnesota, and Department of Biochemistry, University of Illinois, Chicago, Illinois, pp. 105-137.	<input type="checkbox"/>	
	ST. PETER, Wendy L. et al., "Pain Comparison After Subcutaneous Administration of Single-Dose Formulation Versus Multidose Formulation of Epogen in Hemodialysis Patients", American Journal of Kidney Diseases, 32(3):470-74, 1998.	<input type="checkbox"/>	
	Saltzberg, Physicians' Desk Reference, 52 nd Edition, pp. 2776-2777.	<input type="checkbox"/>	
	SAKETOS, Maria et al., "Time-Resolved Immunofluorometric Assay and Specimen Storage Conditions for Measuring Urinary Gonadotropins", Clinical Chemistry, Vol. 40, No. 5, 1974, pp. 749-753.	<input type="checkbox"/>	
	SAXENA, B.B. et al., "Amino Acid Sequence of the β Subunit of Follicle-stimulating Hormone from Human Pituitary Glands", The Journal of Biological Chemistry, Vol. 251, No. 4, pp. 993-1005, February 25, 1976.	<input type="checkbox"/>	
	SERONO Study Report GF 9873, "Evaluation of FSH Formulations claimed in EP-974'359", dated March 22, 2004.	<input type="checkbox"/>	
	SHOEMAKER, J. et al., "New Approaches with the FSH Threshold Principle in Polycystic Ovarian Syndrome", Annals New York Academy of Sciences, pp. 296-300.	<input type="checkbox"/>	
	SHOME, B. et al., "Human Follicle Stimulating Hormone: First Proposal for the Amino Acid Sequence of the Hormone-Specific, β Subunit (hFSH β)", J. Clin. Endocrinol. Metab., Vol. 39, 187, pp. 203-205, 1974.	<input type="checkbox"/>	
	Stemmerow, Physicians' Desk Reference, 24 th Edition, page 867.	<input type="checkbox"/>	
	STRICKLAND, Thomas W. et al., "The Kinetic and Equilibrium Parameters of Subunit Association and Gonadotropin Dissociation", The Journal of Biological Chemistry, 1982, Vol. 257, No. 6 pp. 2954-2960.	<input type="checkbox"/>	
	Package Insert Suprefact.	<input type="checkbox"/>	
	SUGAHARA, Tadashi et al., "Expression of biologically active fusion genes encoding the common α subunit and either the CG β or FSH β subunits: role of a linker sequence", Molecular and Cellular Endocrinology 125 (1996) pp. 71-77.	<input type="checkbox"/>	
	"The United States Pharmacopeia, Twenty-First Revision", United States Pharmacopeial Convention, Inc., Official from January 1, 1985, prepared by the Committee of Revision and published by the Board of Trustees, pp. 1491-1493, 1984.	<input type="checkbox"/>	
	VAHL, et al., "Bioavailability of Recombinant Human Growth Hormone in Different Concentrations and Formulations", Pharmacology & Toxicology 79:144-49, 1996.	<input type="checkbox"/>	
	VOORTMAN, Gerrit et al., "Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (Puregon β) by Pen-injector and syringe", Human Reproduction, 1999, Vol. 14, No. 7, pp. 1698-1702.	<input type="checkbox"/>	

Examiner Signature	/Elly Gerald Stoica/	Date Considered	06/09/2008
--------------------	----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional).

²Applicant is to place a check mark here if English language Translation is attached.

#463330

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/561,529
Sheet	6	of	7	Filing Date	December 20, 2005
				First Named Inventor	SAMARITANI, Fabrizio et al.
				Art Unit	1647
				Examiner Name	Lorraine Spector
				Attorney Docket No.	7541-5

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published			T ^d
		WALLHAUSSER K-H, "Antimicrobial Preservatives in Europe: Experience with Preservatives Used in Pharmaceuticals and Cosmetics", International Symposium on Preservation in Biological Products, San Francisco 1973, Develop. Biol. Standard., Vol. 24, pp. 9-28, 1974.			<input type="checkbox"/>
		ANCHORDOQUY, Thomas J. et al., "Polymers Protect Lactate Dehydrogenase during Freeze-Drying by Inhibiting Dissociation in the Frozen State", Archives of Biochemistry and Biophysics, Vol. 332, No. 2, August 15, 1996, Article No. 0337, pp. 231-238.			<input type="checkbox"/>
		ANIK, Shabbir T. et al., "Adsorption of D-Nal(2) LHRH, a decapeptide, onto glass and other surfaces", Institute of Pharmaceutical Sciences, Syntex Research, Palo Alto, CA, International Journal of Pharmaceutics, Vol. 16, 1983, pp. 181-190.			<input type="checkbox"/>
		BAM, Narendra B. et al. "Stability of Protein Formulations: Investigation of Surfactant Effects by a Novel EPR Spectroscopic Technique", Research Article, Pharmaceutical Research, Vol. 12, No. 1, 1995, pp. 2-11.			<input type="checkbox"/>
		BASELGA, Jose et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185 ^{HER2} Monoclonal Antibody in Patients with HER2/neu-Overexpressing Metastatic Breast Cancer", Journal of Clinical Oncology, Vol. 14, No. 3, March 1996, pp. 737-744.			<input type="checkbox"/>
		BOULET, Louis-Philippe et al., "Inhibitory Effects of an Anti-IgE Antibody E25 on Allergen-induced Early Asthmatic Response", Am J Respir Crit Care Med., Vol. 155, 1997, pp. 1835-1840.			<input type="checkbox"/>
		BUTT, W. R., "The Iodination of Follicle-Stimulating and Other Hormones for Radiimmunoassay", J. Endocr., 1972, Vol. 55, pp. 453-454.			<input type="checkbox"/>
		JENTOFT, Neil, "Why are proteins O-glycosylated?", TIBS 15, August 1990, Elsevier Sciences Publishers Ltd. (UK), pp. 291-294.			<input type="checkbox"/>
		KETELSLEGERS, J.-M et al., "Receptor Binding Properties of ¹²⁵ I-fSH Prepared by Enzymatic Iodination", Submitted August 30, 1974, J. Clin. Endocrinol Metab, Vol. 39, No. 6, 1974, pp. 1159-1162.			<input type="checkbox"/>
		KIBBE, Arthur H. (Editor), "Benzyl Alcohol", Handbook of Pharmaceutical Excipients, Third Edition, American Pharmaceutical Association, 2000, pp.41-43.			<input type="checkbox"/>
		MARANA, R. et al., "Influence of the Purity of the Iodinated Tracer on the Specificity of the Radioimmunoassay of Human Follicle-Stimulating Hormone", Acta Endocrinologica, Vol. 92, 1979, pp. 585-598.			<input type="checkbox"/>
		MIYACHI, Yukitaka, et al., "Structural Integrity of Gonadotropins after Enzymatic Iodination", Biochemical and Biophysical Research Communications, Vol. 46, No. 3, 1972, pp. 1213-1221.			<input type="checkbox"/>
		MIZUTANI, Takaharu et al., "Estimation of Adsorption of Drugs and Proteins on Glass Surfaces with Controlled Pore Glass as a Reference", Journal of Pharmaceutical Sciences, Vol. 67., No. 8, August 1978, American Pharmaceutical Association, pp. 1102-1105			<input type="checkbox"/>
		MIZUTANI, Takaharu, et al., "Study of Protein Adsorption on Glass Surfaces with a Hydrophobic Fluorescent Probe", Chem. Pharm. Bulletin, Volume 32, No. 6, 1984, pp. 2395-2400.			<input type="checkbox"/>

Examiner Signature	/Elly Gerald Stoica/	Date Considered	06/09/2008
--------------------	----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ^dApplicant's unique citation designation number (optional).

²Applicant is to place a check mark here if English language Translation is attached.

#463330

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete If Known</i>	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/561,529
Sheet	7	Of	7	Filing Date	December 20, 2005
				First Named Inventor	SAMARITANI, Fabrizio et al.
				Art Unit	1647
				Examiner Name	Lorraine Spector
				Attorney Docket No. 7541-5	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published			
		NEWMAN et al. "Use of Nonionic Block Copolymers in Vaccines and Therapeutics", Critical Reviews in Therapeutic Drug Carrier Systems, 1998, Vol. 15, No. 2, pp. 89-140.			
		PIKAL, Michael J. et al., "The Effects of Formulation Variables on the Stability of Freeze-Dried Human Growth Hormone", Pharmaceutical Research, Vol. 8, No. 4, 1991, pp. 427-436.			
		PINTO, Heidi et al., "Preparation of High-Quality Iodine-125-Labelled Pituitary Human Follicle-Stimulating Hormone (hFSH) For Radioimmunoassay: Comparison of Enzymatic and Chloramine-T Iodination", Clinica Chimica Acta, Elsevier/North-Holland Biomedical Press, Vol. 76, 1977, pp. 25-34.			
		RATHNAM, P. et al., "Studies on Modification of Tryptophan, Methionine, Tyrosine and Arginine Residues of Human Follicle-Stimulating Hormone and Its Subunits", Biochimica et Biophysica Acta, Vol. 576, 1979, Elsevier/North-Holland Biomedical Press, pp. 81-87.			
		SILBERRING, Jerzy et al., "A Universal and Simple Chloramine T Version for Hormone Iodination", International Journal of Applied Radiation and Isotopes, Vol. 33, 1982, pp. 117-119.			
		STANKOV, B. M. et al., "The Effect of the Purity of the Iodinated Tracer on the Specificity of a Homologous Assay of Ovine Follicle Stimulating Hormone", Biochemistry International, Vol. 12, No. 1, January 1986, pp. 11-19.			
		SUGINAMI, H. et al., "Influence of the Purity of the Iodinated Tracer on the Specificity of the Radiimmunoassay of Human Luteinizing Hormone", Acta Endocrinologica, Vol. 89, 1978, pp. 505-520.			
		SWINYARD, Ewart et al., "Pharmaceutical Necessities", Chapter 68, pp. 1278-1280.			
		TERADA, Shigeyuki, "Iodination of Luteinizing Hormone-Releasing Hormone", Biochemistry 1980, Vol. 19, pp. 2572-2576.			
		"Urofollitropin", European Pharmacopoeia 2001, 1997:0958 (last revised version of 2001), pp. 1-6.			
		VAN den STEEN, Philippe et al., "Concepts and Principles of O-Linked Glycosylation", hCG papers / CTP extensions / Boims papers, Critical Reviews in Biochemistry and Molecular Biology, Vol. 35, No. 3, 1998, pp. 151-208.			
		WANG, Yu-Chang John et al., "Review of Excipients and pH's for Parenteral Products Used in the United States", Journal of the Parenteral Drug Association, Vol. 34, No. 6, November-December, 1980, pp. 452-462.			
		WALSH, Gary, "Pharmaceutical biotechnology products approved within the European Union", European Journal of Pharmaceutics and Biopharmaceutics, Vol. 55, 2003, pp. 3-10.			
		WATERMAN, Kenneth C. et al., "Stabilization of Pharmaceuticals to Oxidative Degradation", Pharmaceutical Development and Technology, Vol. 7, No. 1, 2002, pp. 1-32.			
		WENZEL et al. "Pluronic F127 gel formulations of Deslorelin and GnRH reduce drug degradation and sustain drug release and effect in cattle", Journal of Controlled Release, 2002, Vol. 85, pp. 51-59.			
		XING, Yongna et al., "Threading of a glycosylated protein loop through a protein hole: Implications for combination of human chorionic gonadotropin subunits", Protein Science, Vol. 10, 2001, pp. 226-235.			

Examiner Signature	/Ely Gerald Stoica/	Date Considered	06/09/2008
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional).

¹Applicant is to place a check mark here if English language Translation is attached.

#463330

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.G.S./